42 results about "Platelet production" patented technology

Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.

Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.

Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture. A third invention is a method for producing thrombopoietin, comprising culturing a preadipocyte in a preadipocyte culturing basic medium containing dexamethasone, 3-isobutyl-1-methylxanthine and insulin and collecting thrombopoietin from a culture.

The present invention relates to a synthetic variable region of an immunoglobin construct which contains in at least one of its CDRs a sequence of thrombopoietin, e.g., IEGPTLRQWLAARA or its derivatives. This construct can efficiently bind and activate a thrombopoientin receptor (MPL) leading to stimulation of proliferation, growth or differentiation or modulation of apoptosis of hematopoietic cells, especially platelet progenitor cells. The invention further relates to the use of the synthebody to treat hematopoietic or immune disorders, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions.

Disclosed is a platelet additive solution (PAS) comprising a viscosity increasing agent. The use of a PAS comprising such a viscosity increasing agent, especially at concentrations effective to achieve a viscosity similar to that of blood plasma, promotes platelet recovery during extraction from pooled buffy coats and provides for easier platelet production by maintaining the red cell/platelet-rich-supernatant interface.

The invention relates to the technical field of machines, in particular to a method for artificially synthesizing platelets in vitro in a fluid movement mode. The method comprises a platelet generating device, a vacuum suction device and a platelet enriching device. According to a device and the method for artificially synthesizing platelets in vitro in a fluid movement mode, a turbulence device can be used to simulate a blood turbulence system in the body, induce platelet production, forcibly block quasi-platelet aggregation, and apply a kinetic energy that forces quasi-platelets to split thequasi-platelets self, so that clean platelets can be obtained, and platelet antibodies do not exist. The platelet yield produced by the method is huge, and there is no significant difference in the aspects of functions between mature platelets in the body and the produced platelets. The produced platelets can be directly applied to the clinic, and since the produced platelets is not screened by an in vivo immune system, the produced platelets are not obvious in antigenic property, and no platelet antibodies are generated.

The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.

The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

The invention discloses a method for expressing and purifying a novel cell reprogramming factor. A small ubiquitin-like modifier (SUMO) and a cell penetrating peptide (TAT) are introduced to at the 5'end of a mouse Oct4 gene by a genetic engineering technique. A large number of a TAT-Oct4 protein with a penetrating activity is obtained through in-vitro fusion expression and enzymatic digestion purification, a foundation is laid for the realization of reprogramming cells into iPS cells by using the reprogramming factor protein inducer and the final obtaining of precursor cells for platelet production; and the protein or the nucleotide sequence can be used to induce the production of the iPS cells.

Disclosed herein are compounds, compositions and methods for using such compounds and compositions in the treatment of hyperproliferative conditions, including precancerous and cancerous conditions. In one embodiment, the compounds include resonance modulating compounds that can be used in the method as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. Such resonance modulators have inherent electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of resonance modulators are disclosed, and these substances generally possess resonating intramolecular dipole moments that are capable of electrostatic interaction with biological environments. In certain examples the compounds aggregate at sites of therapeutic action to enhance their therapeutic activity. In other examples the compounds stimulate platelet production.